Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Receivables - Other: 2017-2021

Historic Receivables - Other for Aclaris Therapeutics (ACRS) over the last 4 years, with Dec 2021 value amounting to $24,000.

  • Aclaris Therapeutics' Receivables - Other fell 92.00% to $24,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $24,000, marking a year-over-year decrease of 92.00%. This contributed to the annual value of $24,000 for FY2021, which is 92.00% down from last year.
  • According to the latest figures from FY2021, Aclaris Therapeutics' Receivables - Other is $24,000, which was down 92.00% from $300,000 recorded in FY2020.
  • Aclaris Therapeutics' 5-year Receivables - Other high stood at $300,000 for FY2020, and its period low was -$570,000 during FY2017.
  • Moreover, its 3-year median value for Receivables - Other was $100,000 (2019), whereas its average is $141,333.
  • In the last 5 years, Aclaris Therapeutics' Receivables - Other soared by 200.00% in 2020 and then tumbled by 92.00% in 2021.
  • Aclaris Therapeutics' Receivables - Other (Yearly) stood at -$570,000 in 2017, then reached $100,000 in 2019, then surged by 200.00% to $300,000 in 2020, then crashed by 92.00% to $24,000 in 2021.